<DOC>
	<DOC>NCT00758043</DOC>
	<brief_summary>This study is being conducted to learn more about the safety and effect of telaprevir in combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with hepatitis C who have never been treated for their hepatitis C virus (HCV). The study is designed to look at the relative benefits of 24 or 48 weeks of total treatment in people who respond quickly to a telaprevir-based treatment.</brief_summary>
	<brief_title>A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C Male and female subjects, 18 to 70 years of age, inclusive Genotype 1, chronic hepatitis C with detectable HCV RNA. Screening laboratory values, tests, and physical exam within acceptable ranges Able and willing to follow contraception requirements Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions. Subject has any contraindications to Pegasys® or Copegus® therapy Evidence of hepatic decompensation in cirrhotic subjects History of organ transplant History of, or any current medical condition which could impact the safety of the subject in participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Genotype 1</keyword>
</DOC>